Sharda Cropchem Ltd (Pesticides/Agrochemicals) — fundamental analysis, earnings data, and key metrics. PE: 14.6. ROE: 12.6%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: 15-20% revenue growth expected in FY27 with continued margin expansion
Impact: +₹15 Cr revenue
“We are pleased to report a robust performance driven by strong volume growth and an improved product mix supported by accelerated product registrations.”
What: Gross margins at 34.9% (up 220 bps YoY) with EBITDA margins at 19.1%
“With input cost stabilizing, our gross margins have expanded by 220 basis points to 34.9%. As guided earlier, we expect gross margins to be in the similar range in FY26.”
What: 48-day improvement in working capital days enhancing cash flow generation
“Working capital days stood at 70 days as on 31st December 2025 showing an improvement by 48 days as compared to March 2025.”
Earnings deceleration risks from management commentary
Trigger: Raw material costs increase >10%
Impact: -200 bps margin impact
Management view: With input cost stabilizing, our gross margins have expanded by 220 basis points to 34.9%. As guided earlier, we expect gross margins to be in the similar range in FY26.
Monitor: Raw material cost trends
Trigger: INR strengthens >5% against major currencies
Impact: -100 bps margin impact
Management view: Not explicitly mentioned but significant export exposure
Monitor: Export revenue in INR terms
Key quotes from recent conference calls
“We are pleased to report a robust performance driven by strong volume growth and an improved product mix supported by accelerated product registrations. — Management”
“With input cost stabilizing, our gross margins have expanded by 220 basis points to 34.9%. As guided earlier, we expect gross margins to be in the similar range in FY26. — CFO, Mr. Sales Mahendele”
“Working capital days stood at 70 days as on 31st December 2025 showing an improvement by 48 days as compared to March 2025. — CFO, Mr. Sales Mahendele”
“For FY26 we are on track to maintain healthy EBITDA margins in the range of 18 to 20%. It will be growing and nobody can predict how much. But it is on the way up and we accept, we expect the growth in our total revenue to be around 15 to 15 to 20% in the year FY27. — R.V. Bubna”
Forward-looking targets from management for FY27
Revenue Growth Target
15%
Implied PAT Growth
25%
OPM Guidance
18%
Key Milestones
• Maintain EBITDA margins 18-20% in FY26
• 15-20% revenue growth in FY27
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Sharda Cropchem Ltd's latest quarterly results (Dec 2025) show
Sharda Cropchem Ltd's current PE ratio is 14.6x.
Sharda Cropchem Ltd's price-to-book ratio is 3.1x.
Sharda Cropchem Ltd's fundamental strength based on key financial ratios
Sharda Cropchem Ltd has a debt-to-equity ratio of N/A.
Sharda Cropchem Ltd's return ratios over recent years
Sharda Cropchem Ltd's operating cash flow is positive (FY2025).
Sharda Cropchem Ltd's current dividend yield is 0.98%.
Sharda Cropchem Ltd's shareholding pattern (Dec 2025)
Sharda Cropchem Ltd's promoter holding has remained stable recently.
Sharda Cropchem Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Sharda Cropchem Ltd has 3 key growth catalysts identified from recent earnings analysis
Sharda Cropchem Ltd has 2 key risks worth monitoring
In Q3 FY26, Sharda Cropchem Ltd's management highlighted
Sharda Cropchem Ltd's management has provided the following forward guidance for FY27
Based on quantitative research signals, here is why Sharda Cropchem Ltd may be worth studying
Sharda Cropchem Ltd investment thesis summary:
Sharda Cropchem Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
